Does gliadin increase intestinal permeability by triggering zonulin and loosening tight junctions in susceptible people?

The evidence supports a direct causal link between gliadin exposure and increased intestinal permeability through the zonulin pathway, specifically within populations predisposed to gluten-related disorders.

Clinical and effectiveness evidence

Research indicates that gliadin exposure results in measurable increases in intestinal permeability, though the magnitude and clinical significance vary by individual susceptibility.

• Population-Specific Response: Ex vivo studies using human intestinal biopsies demonstrate that individuals with Celiac Disease (CD) or Non-Celiac Gluten Sensitivity (NCGS) exhibit a significant increase in intestinal permeability when exposed to gliadin. In contrast, healthy controls typically maintain barrier integrity or show only transient, negligible changes.
• Permeability Metrics: In susceptible tissue, gliadin exposure leads to a rapid decrease in trans-epithelial electrical resistance (TEER) and a concomitant increase in the flux of markers like mannitol, indicating a breakdown of the paracellular barrier.
• Genetic Factors: Susceptibility is strongly associated with the HLA-DQ2 or HLA-DQ8 genotypes, which are present in nearly all Celiac patients and a significant portion of those with NCGS.

Mechanistic explanations

The transition from gliadin ingestion to increased permeability involves a precise molecular signaling cascade:

• CXCR3 Binding: Specific gliadin peptides (notably alpha-gliadin) bind to the CXCR3 chemokine receptor on the luminal side of the intestinal epithelium. Individuals with Celiac Disease often exhibit higher expression levels of these receptors.
• Zonulin Release: This binding activates a MyD88-dependent pathway, triggering the rapid secretion of zonulin (pre-haptoglobin-2) into the intestinal lumen. Zonulin is currently the only known physiological modulator that regulates intestinal tight junctions.
• Tight Junction Disassembly: Once released, zonulin binds to the protease-activated receptor 2 (PAR2) and epidermal growth factor receptor (EGFR). This initiates a signaling cascade that results in the phosphorylation and rearrangement of tight junction proteins, including ZO-1, occludin, and claudins.
• Cytoskeletal Contraction: These molecular changes lead to actin polymerization and contraction of the perijunctional actin-myosin ring, physically pulling the tight junctions apart and allowing large molecules to pass between cells.

Clinical implications

For individuals with confirmed gluten susceptibility, the increased permeability caused by gliadin can allow dietary antigens and bacterial toxins to enter the bloodstream, potentially triggering systemic inflammation or autoimmune responses.

• Diagnosis Matters: Because this mechanism is largely attenuated in the healthy population, the practical risks of gliadin-induced permeability are most relevant for those experiencing gastrointestinal or extra-intestinal symptoms associated with gluten.
• Therapeutic Targets: Understanding the zonulin pathway has led to the development of zonulin inhibitors (such as larazotide acetate), which are being investigated in clinical trials to help maintain tight junction integrity in Celiac patients.

Bottom line

Gliadin triggers a specific CXCR3-zonulin signaling pathway that loosens intestinal tight junctions and increases permeability in susceptible individuals, such as those with Celiac Disease or NCGS. While this mechanism is well-documented in these groups, it does not typically lead to significant or sustained "leaky gut" in the healthy general population.